A5054120621- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Hepatitis Viruses Studies and Epidemiology
- Hepatitis C virus research
- Nutrition and Health in Aging
- MRI in cancer diagnosis
- Ultrasound and Hyperthermia Applications
- Abdominal vascular conditions and treatments
- Hepatitis B Virus Studies
- Drug-Induced Hepatotoxicity and Protection
- Diet, Metabolism, and Disease
- Renal Transplantation Outcomes and Treatments
- Animal Virus Infections Studies
- Liver physiology and pathology
- Hormonal Regulation and Hypertension
- SARS-CoV-2 and COVID-19 Research
- Eicosanoids and Hypertension Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Viral gastroenteritis research and epidemiology
- Advanced MRI Techniques and Applications
- COVID-19 Clinical Research Studies
- HIV-related health complications and treatments
University Hospital of Bern
2016-2025
University of Bern
2016-2025
Swiss HIV Cohort Study
2023-2025
University Hospital Münster
2024
Kantonsspital Baselland
2023
University of Basel
2023
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2023
Hôpital Beau-Séjour
2023
Financial Research (Hungary)
2023
The Geneva Association
2018-2023
This guidance provides a data-supported approach to risk stratification, diagnosis, and management of patients with cirrhosis portal hypertension (PH). A document is different from guideline. Guidelines are developed by multidisciplinary panel experts who rate the quality (level) evidence strength each recommendation using Grading Recommendations Assessment, Development, Evaluation system. in topic, statements, not recommendations, put forward help clinicians understand implement most recent...
Abstract We present here the first update of 2013 EFSUMB (European Federation Societies for Ultrasound in Medicine and Biology) Guidelines Recommendations on clinical use elastography, focused assessment diffuse liver disease. The part (long version) these deals with basic principles elastography provides an how technology has changed. practical advantages disadvantages associated each techniques are described, guidance is provided regarding optimization scanning technique, image display,...
In patients with compensated advanced chronic liver disease (cACLD), the presence of clinically significant portal hypertension (CSPH) and varices needing treatment (VNT) bears prognostic therapeutic implications. Our aim was to develop noninvasive tests-based risk prediction models provide a point-of-care assessment cACLD patients. We analyzed 518 from five centers in Europe/Canada paired tests (liver stiffness measurement [LSM] by transient elastography, platelet count, spleen diameter...
Obesity is associated with an aggressive course in chronic viral hepatitis; however, its impact the development of clinical decompensation (CD) patients established cirrhosis uncertain. We evaluated role obesity, relationship to other recognized predictors, CD compensated cirrhosis. The study population, a subset included randomized trial beta-blockers prevention varices whom data on body mass index (BMI) was available, consisted 161 Laboratory tests and portal pressure (assessed by hepatic...
Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) overweight/obese patients with if loss reduces pressure this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled compensated hypertension (hepatic venous gradient [HVPG] ≥6 mm Hg), body mass index (BMI) ≥26 kg/m2 an intensive 16-week LS intervention...
Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening endoscopy a platelet count >150 × 109 cells/L and stiffness measurement (LSM) <20 kPa (Baveno VI criteria). However, the total number of avoided endoscopies using this rule is relatively low. We aimed at expanding Baveno criteria validating them in additional cohorts. from Anticipate cohort (499 patients cACLD different etiologies) were used to study performance thresholds platelets LSM for...
Abstract The present, updated document describes the fourth iteration of recommendations for hepatic use contrast enhanced ultrasound (CEUS), first initiated in 2004 by European Federation Societies Ultrasound Medicine and Biology (EFSUMB). previous editions guidelines reflected changes available agents not only but also non-hepatic applications. 2012 guideline requires updating as previously differences were precisely described phases well handling clearly indicated. In addition, more...